{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T18:02:28Z","timestamp":1781805748131,"version":"3.54.5"},"reference-count":38,"publisher":"Impact Journals, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,2,2]]},"DOI":"10.18632\/oncotarget.6742","type":"journal-article","created":{"date-parts":[[2015,12,31]],"date-time":"2015-12-31T21:27:01Z","timestamp":1451597221000},"page":"6175-6187","source":"Crossref","is-referenced-by-count":17,"title":["FZD7 regulates BMSCs-mediated protection of CML cells"],"prefix":"10.18632","volume":"7","author":[{"given":"Na","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology Qilu Hospital, Shandong University, Ji'nan 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaolei","family":"Zang","sequence":"additional","affiliation":[{"name":"Department of Hematology Qilu Hospital, Shandong University, Ji'nan 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology Qilu Hospital, Shandong University, Ji'nan 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology Qilu Hospital, Shandong University, Ji'nan 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology Qilu Hospital, Shandong University, Ji'nan 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, Ji'nan 250014, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Hematology Qilu Hospital, Shandong University, Ji'nan 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoxin","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology Qilu Hospital, Shandong University, Ji'nan 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Hematology Qilu Hospital, Shandong University, Ji'nan 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,12,23]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Kantarjian","year":"1999","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Powell","year":"2006","journal-title":"N Engl J Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1634\/theoncologist.2009-0297","article-title":"Why doesn't imatinib cure chronic myeloid leukemia?","volume":"15","author":"Redner","year":"2010","journal-title":"Oncologist"},{"key":"4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.critrevonc.2013.07.017","article-title":"The one-two punch: combination treatment in chronic myeloid leukemia","volume":"88","author":"Pinilla-Ibarz","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"5","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-13-0410","article-title":"Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CMLand","volume":"13","author":"Nagler","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00204-014-1226-6","article-title":"Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway","volume":"89","author":"Guo","year":"2015","journal-title":"Arch Toxicol"},{"key":"7","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1101\/gad.244772.114","article-title":"Wnt some lose some: transcriptional governance of stem cells by Wnt\/beta-catenin signaling","volume":"28","author":"Fuchs","year":"2014","journal-title":"Genes Dev"},{"key":"8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0002-9440(10)65297-2","article-title":"Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway","volume":"154","author":"Pals","year":"1999","journal-title":"Am J Pathol"},{"key":"9","doi-asserted-by":"publisher","first-page":"20697","DOI":"10.18632\/oncotarget.4136","article-title":"AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pharmthera.2013.01.002","article-title":"The WNT signaling pathway from ligand secretion to gene transcription: molecular mechanisms and pharmacological targets","volume":"138","author":"Gosens","year":"2013","journal-title":"Pharmacol Ther"},{"key":"11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.molcel.2013.05.013","article-title":"TRIB2 acts downstream of Wnt\/TCF in liver cancer cells to regulate YAP and C\/EBPalpha function","volume":"51","author":"Mao","year":"2013","journal-title":"Mol Cell"},{"key":"12","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling","volume":"121","author":"Bhatia","year":"2013","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Kantarjian","year":"2013","journal-title":"Blood"},{"key":"14","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.cellsig.2011.12.009","article-title":"Frizzled7 as an emerging target for cancer therapy","volume":"24","author":"Li","year":"2012","journal-title":"Cell Signal"},{"key":"15","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/sj.bjc.6605307","article-title":"Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells","volume":"101","author":"Hinoda","year":"2009","journal-title":"Br J Cancer"},{"key":"16","first-page":"1001","article-title":"DeltaNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling","volume":"16","author":"Kannan","year":"2014","journal-title":"Nat Cell Biol"},{"key":"17","doi-asserted-by":"crossref","first-page":"e98861","DOI":"10.1371\/journal.pone.0098861","article-title":"Frizzled 7 expression is positively regulated by SIRT1 and beta-catenin in breast cancer cells","volume":"9","author":"Pruitt","year":"2014","journal-title":"PLoS One"},{"key":"18","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/10428190802553257","article-title":"Down-regulation of Notch-1 increases co-cultured Jurkat cell sensitivity to chemotherapy","volume":"50","author":"Ji","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jhep.2007.12.020","article-title":"Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt\/beta-catenin signaling pathway in hepatocellular carcinoma cells","volume":"48","author":"Wands","year":"2008","journal-title":"J Hepatol"},{"key":"20","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1038\/onc.2011.145","article-title":"FZD7 has a critical role in cell proliferation in triple negative breast cancer","volume":"30","author":"Yen","year":"2011","journal-title":"Oncogene"},{"key":"21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ydbio.2013.02.024","article-title":"Different thresholds of Wnt-Frizzled 7 signaling coordinate proliferation, morphogenesis and fate of endoderm progenitor cells","volume":"378","author":"Zorn","year":"2013","journal-title":"Dev Biol"},{"key":"22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.18632\/oncotarget.333","article-title":"Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy","volume":"2","author":"Turhan","year":"2011","journal-title":"Oncotarget"},{"key":"23","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.4161\/cc.4.12.2259","article-title":"Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance","volume":"4","author":"Blagosklonny","year":"2005","journal-title":"Cell Cycle"},{"key":"24","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1126\/science.1164390","article-title":"Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells","volume":"322","author":"Sipkins","year":"2008","journal-title":"Science"},{"key":"25","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-14-3379","article-title":"Microenvironmental remodeling as a parameter and prognostic factor of heterogeneous leukemogenesis in acute myelogenous leukemia","volume":"75","author":"Oh","year":"2015","journal-title":"Cancer Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","article-title":"Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia","volume":"21","author":"Bhatia","year":"2012","journal-title":"Cancer Cell"},{"key":"27","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2011-04-348151","article-title":"Functional inhibition of osteoblastic cells in anmouse model of myeloid leukemia","volume":"119","author":"Calvi","year":"2012","journal-title":"Blood"},{"key":"28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Passegue","year":"2013","journal-title":"Cell Stem Cell"},{"key":"29","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjh.12725","article-title":"Advances in understanding the leukaemia microenvironment","volume":"164","author":"Konopleva","year":"2014","journal-title":"Br J Haematol"},{"key":"30","first-page":"484","article-title":"Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin","volume":"4","author":"Blagosklonny","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"31","doi-asserted-by":"publisher","first-page":"8637","DOI":"10.18632\/oncotarget.2353","article-title":"Selective JAK2\/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem\/progenitor cells","volume":"5","author":"Jiang","year":"2014","journal-title":"Oncotarget"},{"key":"32","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Weissman","year":"2004","journal-title":"N Engl J Med"},{"key":"33","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2007.12.002","article-title":"Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia","volume":"35","author":"Cortes","year":"2008","journal-title":"Semin Oncol"},{"key":"34","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells","volume":"12","author":"Reya","year":"2007","journal-title":"Cancer Cell"},{"key":"35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/leu.2008.262","article-title":"beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia","volume":"23","author":"Li","year":"2009","journal-title":"Leukemia"},{"key":"36","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","article-title":"Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML","volume":"10","author":"Armstrong","year":"2012","journal-title":"Cell Stem Cell"},{"key":"37","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.emboj.7601485","article-title":"Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation","volume":"26","author":"Gambacorti-Passerini","year":"2007","journal-title":"EMBO J"},{"key":"38","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-06-0025","article-title":"Janus kinase 2: a critical target in chronic myelogenous leukemia","volume":"66","author":"Arlinghaus","year":"2006","journal-title":"Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T17:18:06Z","timestamp":1589217486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,23]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,2,2]]}},"alternative-id":["6742","26716419"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.6742","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,23]]}}}